Kbect-LS Tablet contains Levosulpiride 25 mg, a selective dopamine D2 receptor antagonist with prokinetic and antipsychotic properties. It is primarily indicated for the treatment of gastrointestinal motility disorders such as functional dyspepsia, gastroesophageal reflux disease (GERD), and delayed gastric emptying. Levosulpiride acts by enhancing the release of acetylcholine in the enteric nervous system, thereby improving gastric motility and accelerating gastric emptying. Additionally, it exerts central dopaminergic antagonism, which may contribute to its efficacy in alleviating symptoms of nausea, vomiting, and abdominal discomfort associated with gastrointestinal dysfunction. Kbect-LS is also utilized in certain psychiatric conditions, including schizophrenia and depressive disorders, due to its antipsychotic and antidepressant effects mediated through modulation of dopaminergic pathways. The recommended dosage and duration of therapy should be individualized based on the clinical condition and patient response. Common adverse effects may include drowsiness, dizziness, and extrapyramidal symptoms; therefore, caution is advised in patients with a history of movement disorders or those receiving concomitant neuroleptic therapy. Kbect-LS should be used under medical supervision, with periodic monitoring for efficacy and safety to ensure optimal therapeutic outcomes.